GlassScriptPhysician profile
Rohit Gosain
NPI 1932515210
$19,809.92
in general payments reported to CMS, 2019-2025
31 companies · $12K in 2025
The $12K reported for 2025 was more than what 90% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $511 · 2020: $227 · 2021: $305 · 2022: $274 · 2023: $60.28 · 2024: $6,152 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,000 · Grant: $5,550 · Food and Beverage: $2,283 · Consulting Fee: $1,975 · Travel and Lodging: $1,062 · Long Term Medical Supply Or Device Loan: $499 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,000.00 |
| Grant | $5,550.00 |
| Food and Beverage | $2,282.84 |
| Consulting Fee | $1,975.00 |
| Travel and Lodging | $1,061.54 |
| Long Term Medical Supply Or Device Loan | $498.50 |
| Education | $124.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $5,865.62 | 2019-2025 | Tagrisso, Calquence, Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $5,062.25 | 2024-2025 | Ninlaro, Fruzaqla |
| Merck Sharp & Dohme LLC | $3,220.88 | 2024-2025 | Keytruda |
| Eisai INC. | $2,131.28 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $649.34 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $637.03 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $503.92 | 2021-2025 | Opdivo, Pomalyst |
| Astellas Pharma US INC | $199.72 | 2019-2025 | Padcev |
| Pfizer INC. | $189.00 | 2024-2025 | |
| Janssen Biotech, INC. | $170.84 | 2024-2025 | Erleada, Akeega, Carvykti |
| Glaxosmithkline, LLC. | $159.49 | 2023-2025 | Ojjaara, Jemperli, Zejula |
| Gilead Sciences, INC. | $142.32 | 2024 | Trodelvy |
| Celgene Corporation | $126.79 | 2022-2025 | Reblozyl, Opdivo |
| Seagen INC. | $99.00 | 2025 | |
| Genzyme Corporation | $94.35 | 2024-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $74.80 | 2024-2025 | Xt Cdx |
| Sumitomo Pharma America, INC. | $69.27 | 2024-2025 | Orgovyx |
| Amgen INC. | $64.99 | 2021 | |
| Abbvie INC. | $47.56 | 2025 | |
| Sun Pharmaceutical Industries INC. | $38.68 | 2022-2023 | Yonsa, Odomzo |
| Array Biopharma INC | $32.92 | 2024-2025 | Mektovi, Braftovi, Lorbrena |
| Incyte Corporation | $29.18 | 2024 | Monjuvi, Pemazyre |
| Sobi, INC | $28.76 | 2022 | |
| Janssen Pharmaceuticals, INC | $25.72 | 2024 | |
| Daiichi Sankyo INC. | $23.69 | 2024 | Enhertu |
| Pharmacosmos Therapeutics INC. | $23.28 | 2024 | Monoferric |
| Beigene USA, INC. | $21.60 | 2024 | Brukinsa |
| Adc Therapeutics America, INC. | $21.11 | 2024 | |
| Beone Medicines USA, INC. | $20.72 | 2025 | Brukinsa |
| Baxter Healthcare | $19.97 | 2021 | |
| Adaptive Biotechnologies Corporation | $15.84 | 2025 | Clonoseq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rohit Gosain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.